09:54 AM EDT, 09/09/2024 (MT Newswires) -- Cartesian Therapeutics ( RNAC ) said Monday its Descartes-08 cell therapy candidate received rare pediatric disease designation from the US Food and Drug Administration for the treatment of juvenile dermatomyositis.

The cell therapy candidate is designed to be administered without preconditioning chemotherapy and doesn't use integrating vectors, the company said.

The regulator grants the designation for serious and life-threatening diseases that mainly affect children aged 18 years or younger and fewer than 200,000 people in the US, Cartesian said.

The company's shares were up more than 1% in recent trading.

Price: 13.15, Change: +0.17, Percent Change: +1.31